公开(公告)号：US20110264762A1

公开(公告)日：2011-10-27

申请号：US12784205

申请日：2010-05-20

Applicant: Yan Fu

Inventor： Yan Fu

IPC: G06F15/16

CPC classification number: G06F16/9537

Abstract: An approach is provided for resolving a network address of one or more of items included in a request for web content based, at least in part, on location information. The network address of the items corresponds to at least one of a plurality of sources for retrieving the items. Resolving of the network address of the items is based at least in part on a persistent data element specifying pertinent location information.

Abstract translation: 提供了一种用于至少部分地基于位置信息来解决包括在对web内容的请求中的一个或多个项目的网络地址的方法。 项目的网络地址对应于用于检索项目的多个源中的至少一个。 解决项目的网络地址至少部分地基于指定相关位置信息的持久数据元素。

公开(公告)号：US20110124319A1

公开(公告)日：2011-05-26

申请号：US12626418

申请日：2009-11-25

Applicant: Yan Fu

Inventor： Yan Fu

IPC: H04M3/42 ,  G06F15/16

CPC classification number: H04L67/02 ,  H04L67/303

Abstract: Techniques to ensure that user agent information is transported includes determining whether both a type field and a client platform information field are included in a first portion of a uniform resource locator field (URL) of a hypertext transfer protocol (HTTP) request message received from a remote client process. The first portion is different from a domain portion of the URL. The type field holds data that indicates whether the remote client inserted the client information field into a URL of an original HTTP request message. If both the type field and the client platform information field are included, then it is determined, based on data in the type field, whether to include both the type field and the client platform information field in a first portion of a URL in a link in a HTTP response message. The HTTP response message is sent to the remote client process.

Abstract translation: 确保用户代理信息被传送的技术包括确定类型字段和客户端平台信息字段是否被包括在从一个或多个客户机平台信息接收到的超文本传输​​协议（HTTP）请求消息的统一资源定位符字段（URL）的第一部分中 远程客户端进程。 第一部分与URL的域部分不同。 类型字段保存指示远程客户端是否将客户端信息字段插入到原始HTTP请求消息的URL中的数据。 如果包括类型字段和客户端平台信息字段，则基于类型字段中的数据确定是否将链接中的URL的第一部分中的类型字段和客户端平台信息字段都包括在一起 在HTTP响应消息中。 HTTP响应消息被发送到远程客户端进程。

公开(公告)号：US20110027221A1

公开(公告)日：2011-02-03

申请号：US12529981

申请日：2008-09-24

Applicant: Yan Fu ,  Zailin Yu

Inventor： Yan Fu ,  Zailin Yu

IPC: A61K38/20 ,  A61K38/16 ,  A61K38/30 ,  A61K38/22 ,  A61K38/38 ,  A61K38/21 ,  A61Q19/00 ,  A61Q19/08

CPC classification number: A61K8/64 ,  A61K8/99 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/107 ,  A61K36/064 ,  A61K38/1808 ,  A61K38/1816 ,  A61K38/1858 ,  A61K38/193 ,  A61K38/20 ,  A61K38/217 ,  A61K38/30 ,  A61K38/38 ,  A61Q5/12 ,  A61Q11/00 ,  A61Q19/00 ,  A61Q19/02 ,  A61Q19/08 ,  C07K14/475 ,  C07K2319/00 ,  A61K2300/00

Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.

Abstract translation: 本发明提供了一种重组融合蛋白，其能刺激皮肤和表皮细胞的复原和再激活，以改善皮肤外观，使皱纹和雀斑平滑，以及美白皮肤。 特别地，本发明提供各种类型的用于改善皮肤的产品，其含有人血清白蛋白（HSA）与细胞因子肽（EGF，FGF，KGF，HGH，HGF，PDGF，GCSF，干扰素，IL-11或 IGF）通过基因工程技术。 融合蛋白可以独立使用或与酵母发酵产物组合使用，或与各种乳化剂，增稠剂，保湿剂，防腐剂，酵母和发酵剂组合使用。

公开(公告)号：US20100332332A1

公开(公告)日：2010-12-30

申请号：US12495407

申请日：2009-06-30

Applicant: Arto Heikki Tapio Lammintaus ,  Yan Fu

Inventor： Arto Heikki Tapio Lammintaus ,  Yan Fu

IPC: G06Q30/00 ,  G06F21/00

CPC classification number: G06Q30/0276 ,  G06Q30/02

Abstract: An approach is provided for freely distributing digital content with advertisement. A digital content and advertising platform receives digital content and determines whether to permit free distribution of the digital content. The digital content and advertising platform then generates a digital medium to include the digital content, an advertisement, and a separation criterion for separating the advertisement from the digital content.

Abstract translation: 提供了一种通过广告自由分发数字内容的方法。 数字内容和广告平台接收数字内容并确定是否允许免费分发数字内容。 然后，数字内容和广告平台生成数字媒体以包括数字内容，广告和用于将广告与数字内容分离的分离标准。

公开(公告)号：US07654724B2

公开(公告)日：2010-02-02

申请号：US10967510

申请日：2004-10-18

Applicant: Yu-Yan Fu ,  Ying Szu Tu

Inventor： Yu-Yan Fu ,  Ying Szu Tu

IPC: F21V7/04

CPC classification number: G02F1/133608 ,  G02F1/133604

Abstract: A backlight module and a ground plate thereof. The backlight module includes a plurality of lamps and a ground plate. Each lamp includes a tube body and an electrode. The ground plate includes a plurality of notches, corresponding to the electrode, to hold the electrode. The ground plate also includes a first side portion, a bottom portion, and a second side portion. The notches are formed at the first side portion. The bottom portion is connected to the first side portion. The second side portion is connected to the bottom portion. The first side portion is closer to the tube body than the second side portion.

Abstract translation: 背光模块及其接地板。 背光模块包括多个灯和接地板。 每个灯包括管体和电极。 接地板包括对应于电极的多个凹口以保持电极。 接地板还包括第一侧部分，底部部分和第二侧部分。 凹口形成在第一侧部分。 底部连接到第一侧部。 第二侧部连接到底部。 第一侧部比第二侧部更靠近管体。

公开(公告)号：US20090280085A1

公开(公告)日：2009-11-12

申请号：US12475490

申请日：2009-05-30

Applicant: Yan Fu ,  Zailin Yu

Inventor： Yan Fu ,  Zailin Yu

IPC: A61K38/21 ,  C07K19/00 ,  A61K38/16 ,  A61P37/04

CPC classification number: A61K38/38 ,  A61K47/643 ,  A61K47/646 ,  C07H21/04 ,  C07K14/47 ,  C07K14/475 ,  C07K14/505 ,  C07K14/52 ,  C07K14/54 ,  C07K14/5403 ,  C07K14/5431 ,  C07K14/765 ,  C07K14/79 ,  C07K2319/00 ,  Y02A50/463 ,  A61K2300/00

Abstract: Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have 3-10 times longer acting function than interferon in vivo. These novel long acting interferon analogs can be used in treatment of patients with viral infection, such as SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma. They also have a 3-5 times longer shelf-life compared with interferon.

Abstract translation: 为干扰素类似物提供了组合物，试剂盒和方法，以促进一般健康或治疗疾病。 人类干扰素类似物通过干扰素与人血清白蛋白的融合来制备。 生物测定显示具有相同抗细胞病毒侵袭能力的干扰素类似物在体内比干扰素具有3-10倍的作用功能。 这些新型长效干扰素类似物可用于治疗病毒感染患者，如SARS病毒，HIV，HCV，HBV或HAV，以及癌症疾病如白血病和恶性黑色素瘤。 与干扰素相比，它们的保质期还有3-5倍。

公开(公告)号：US07572437B2

公开(公告)日：2009-08-11

申请号：US10851666

申请日：2004-05-24

Applicant: Yan Fu ,  Zailin Yu

Inventor： Yan Fu ,  Zailin Yu

IPC: A61K38/21 ,  A61K39/00 ,  A61K45/00 ,  C07H21/02

CPC classification number: A61K38/38 ,  A61K47/643 ,  A61K47/646 ,  C07H21/04 ,  C07K14/47 ,  C07K14/475 ,  C07K14/505 ,  C07K14/52 ,  C07K14/54 ,  C07K14/5403 ,  C07K14/5431 ,  C07K14/765 ,  C07K14/79 ,  C07K2319/00 ,  Y02A50/463 ,  A61K2300/00

Abstract: Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have 3-10 times longer acting function than interferon in vivo. These novel long acting interferon analogs can be used in treatment of patients with viral infection, such as SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma. They also have a 3-5 times longer shelf-life compared with interferon.

公开(公告)号：US20090147182A1

公开(公告)日：2009-06-11

申请号：US12371656

申请日：2009-02-16

Applicant: Shin-Li Chen ,  Yu-Yan Fu

Inventor： Shin-Li Chen ,  Yu-Yan Fu

IPC: G02F1/13357

CPC classification number: G02F1/133608 ,  G02F1/133606 ,  G02F2201/54

Abstract: A diffusion assembly for a liquid crystal display includes a diffuser and an optical film. The diffuser has at least one hanging element and a fixing element. The optical film has at least one hole, wherein the at least one hanging element is engaged with the at least one hole of the optical film, and the fixing element is substantially L-shaped and holds the optical film.

Abstract translation: 用于液晶显示器的扩散组件包括扩散器和光学膜。 扩散器具有至少一个悬挂元件和固定元件。 所述光学膜具有至少一个孔，其中所述至少一个悬挂元件与所述光学膜的所述至少一个孔接合，并且所述固定元件基本上为L形并且保持所述光学膜。

公开(公告)号：US20090053173A1

公开(公告)日：2009-02-26

申请号：US10851666

申请日：2004-05-24

Applicant: Yan Fu ,  Zailin Yu

Inventor： Yan Fu ,  Zailin Yu

IPC: A61K38/21 ,  C07K14/52 ,  A61P43/00

CPC classification number: A61K38/38 ,  A61K47/643 ,  A61K47/646 ,  C07H21/04 ,  C07K14/47 ,  C07K14/475 ,  C07K14/505 ,  C07K14/52 ,  C07K14/54 ,  C07K14/5403 ,  C07K14/5431 ,  C07K14/765 ,  C07K14/79 ,  C07K2319/00 ,  Y02A50/463 ,  A61K2300/00

Abstract: Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have 3-10 times longer acting function than interferon in vivo. These novel long acting interferon analogs can be used in treatment of patients with viral infection, such as SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma. They also have a 3-5 times longer shelf-life compared with interferon.

Abstract translation: 为干扰素类似物提供了组合物，试剂盒和方法，以促进一般健康或治疗疾病。 人类干扰素类似物通过干扰素与人血清白蛋白的融合来制备。 生物测定显示具有相同抗细胞病毒侵袭能力的干扰素类似物在体内比干扰素具有3-10倍的作用功能。 这些新型长效干扰素类似物可用于治疗病毒感染患者，如SARS病毒，HIV，HCV，HBV或HAV，以及癌症疾病如白血病和恶性黑色素瘤。 与干扰素相比，它们的保质期还有3-5倍。

公开(公告)号：US07442371B2

公开(公告)日：2008-10-28

申请号：US11825686

申请日：2007-07-08

Applicant: Zailin Yu ,  Yan Fu

Inventor： Zailin Yu ,  Yan Fu

IPC: C07K14/52 ,  A61K38/19

CPC classification number: A61K38/38 ,  A61K47/643 ,  A61K47/646 ,  C07H21/04 ,  C07K14/47 ,  C07K14/475 ,  C07K14/505 ,  C07K14/52 ,  C07K14/54 ,  C07K14/5403 ,  C07K14/5431 ,  C07K14/765 ,  C07K14/79 ,  C07K2319/00 ,  Y02A50/463 ,  A61K2300/00

Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.

Abstract translation: 提供了通过使用人血清白蛋白（HSA）和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物，试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽，并且优选地，当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中，可以改善体内生物活性分子的稳定性，并且由于体内毒性降低和持久的治疗效果，治疗指数增加。 此外，提供制造方法用于在酵母中有效，成本有效地生产这些重组蛋白。